Patient acquisition measured to the attended appointment

How to calculate patient acquisition cost properly

Patient acquisition cost is total marketing spend for a period divided by the number of new patients who attended in that period. Both halves of that sentence are where practices go wrong.

Total spend means everything: media, the agency retainer, call tracking and software subscriptions, creative production, the landing page build amortised across its useful life, and any commission paid to aggregator platforms. Media spend alone understates the real figure substantially, and it is the version most commonly quoted.

New attended patients means people who walked in and were seen for the first time. Not enquiries. Not form fills. Not calls. Not bookings. An enquiry is a request; a booking is an intention; only attendance is a patient. The gap between enquiry count and attendance count is frequently large enough to double the true cost figure, which is exactly why the enquiry-level version is the one that gets reported.

• Numerator: media plus retainer plus tooling plus production plus platform commissions
• Denominator: new patients attended, counted from the appointment system
• Segment by channel and by service — a blended average hides both the winner and the loser
• Allow for the lag between spend and attendance, especially for high-consideration treatments

Lifetime value decides what you can afford to spend

Acquisition cost means nothing on its own. It only becomes a decision once you set it against what a patient is worth, and that is where healthcare differs sharply from most sectors, because the spread between service lines is enormous.

A general physician earning a consultation fee on a first visit, with sporadic repeat visits, can justify only a modest acquisition cost. A dental practice where a first visit routinely leads to a multi-visit treatment plan operates in an entirely different band. An IVF clinic, where a single cycle carries a substantial fee and often leads to further cycles, can rationally spend an order of magnitude more per acquired patient than the GP down the corridor — and will be bidding against them for some of the same keywords.

This is why a benchmark cost per lead borrowed from another practice is useless. The right question is never whether ₹1,800 per enquiry is expensive; it is what proportion of the patient's realistic lifetime value that represents in your specialty.

Speed to lead is the cheapest improvement available

Conversion from enquiry to contact collapses with elapsed time. The steepest fall happens inside the first hour, and by the time a day has passed the patient has usually contacted two or three other practices and booked with whoever answered first. Healthcare is not special here, except that the decision is often urgent, which makes the decay steeper still.

The practical reality in most clinics we audit is a phone that rings out at 7pm, a WhatsApp message read the next morning, and a form enquiry from Saturday that is called on Tuesday. None of that shows in the marketing report, because the enquiry was recorded. It only shows in attendance, which nobody was measuring.

The fixes are unglamorous and cheap: an instant automated acknowledgement so the patient knows they have been heard, a missed-call alert that creates a callback task, a templated WhatsApp response outside hours, and a service-level target the front desk is actually measured against. Practices routinely recover more attended patients from this than from a proportionate increase in ad budget.

No-show economics and the patient you already paid for

A no-show rate of a fifth to a third is common in Indian outpatient settings, and it is an acquisition problem disguised as an operations statistic. If you acquired a patient for ₹2,000 and a quarter of them never arrive, your real cost per attended patient is ₹2,667. Cutting no-shows from twenty-five percent to twelve is arithmetically identical to a substantial reduction in media cost, and it is usually faster to achieve.

Then there is recall, which is the cheapest patient available and the one most practices ignore completely. A patient due for a six-month review, a lapsed treatment plan, an annual health check — you have already paid to acquire these people once, you already hold their contact details lawfully under the DPDP Act 2023 as long as you have a proper basis and honour withdrawal of consent, and reaching them costs a message. Practices that build a recall programme frequently find it produces attended patients at a fraction of the cost of any paid channel.

• Model no-shows into acquisition cost rather than treating them as an operational footnote
• Waitlist backfill converts a cancellation into an attended patient at zero media cost
• Recall lists should be generated from clinical records, not from a marketing database
• Honour consent withdrawal and keep contact preferences current under the DPDP Act 2023

Spend against capacity, not against ambition

The last discipline is capacity awareness. Demand generation that exceeds what the schedule can absorb creates long waits, rushed consultations and a spike in negative reviews — which then raises acquisition cost across every channel, because reviews gate conversion everywhere.

The correct planning unit is open slots by service and by day. If Tuesday afternoons in periodontics are empty and Saturday mornings are booked three weeks out, that is a targeting and scheduling instruction, not a reason to raise the whole budget. Marketing that respects the schedule performs better on cost per attended patient than marketing that simply buys more of everything.